We previously analyzed a TKI resistance dataset (GSE76068) from a mouse model and showed that RRM2 is closely associated with sunitinib resistance in renal cancer, and this effect is mediated by its activation of the AKT signaling pathway 28. This evidence concerns the gene AKT1 and renal carcinoma.